超声影像组学列线图预测乳腺癌新辅助化疗敏感性的构建与验证
该回顾性研究纳入288例接受新辅助化疗的乳腺癌患者,基于治疗前超声提取影像组学特征,联合临床特征构建超声影像组学列线图(RU),用于预测对化疗敏感(Grade 4-5)的患者。RU在训练组AUC为0.863(95%CI 0.814-0.963),验证组AUC为0.854(95%CI 0.776-0.931),决策曲线显示临床效用良好。
要点
- RU模型可辅助筛选对新辅助化疗敏感的乳腺癌患者。
- Grade 4-5缓解预测在验证组AUC达0.854。
- 列线图联合临床特征优于单独影像组学或临床模型。
核心结论
- 基于治疗前超声的影像组学列线图对预测乳腺癌新辅助化疗敏感(Grade 4-5)具有潜在价值。
研究设计与样本
- 回顾性研究队列,纳入288例术前接受新辅助化疗的乳腺癌患者。
- 基于治疗前超声提取影像组学特征,采用LASSO回归筛选特征并建立Rad-score,联合独立临床特征构建RU列线图。
- 通过校准曲线、AUC和决策曲线分析(DCA)评估RU性能。
诊断标准与关键数值
- 训练队列筛选出9个特征构建影像组学标签。
- RU识别Grade 4-5患者的训练组AUC为0.863(95%CI 0.814-0.963),验证组AUC为0.854(95%CI 0.776-0.931)。
- RU性能显著优于临床模型和单独Rad-score(p<0.05,Delong检验)。
临床应用与阅片要点
- 治疗前超声影像组学列线图可用于辅助预测乳腺癌新辅助化疗敏感性,帮助临床决策。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To construct a combined radiomics model based on pre-treatment ultrasound for predicting of advanced breast cancers sensitive to neoadjuvant chemotherapy (NAC).
METHODS: A total of 288 eligible breast cancer patients who underwent NAC before surgery were enrolled in the retrospective study cohort. Radiomics features reflecting the phenotype of the pre-NAC tumors were extracted. With features selected using the least absolute shrinkage and selection operator (LASSO) regression, radiomics signature (Rad-score) was established based on the pre-NAC ultrasound. Then, radiomics nomogram of ultrasound (RU) was established on the basis of the best radiomic signature incorporating independent clinical features. The performance of RU was evaluated in terms of calibration curve, area under the curve (AUC), and decision curve analysis (DCA).
RESULTS: Nine features were selected to construct the radiomics signature in the training cohort. Combined with independent clinical characteristics, the performance of RU for identifying Grade 4-5 patients was significantly superior than the clinical model and Rad-score alone (p < 0.05, as per the Delong test), which achieved an AUC of 0.863 (95% CI, 0.814-0.963) in the training group and 0.854 (95% CI, 0.776-0.931) in the validation group. DCA showed that this model satisfactory clinical utility, suggesting its robustness as a response predictor.
CONCLUSION: This study demonstrated that RU has a potential role in predicting drug-sensitive breast cancers.
ADVANCES IN KNOWLEDGE: Aiming at early detection of Grade 4-5 breast cancer patients, the radiomics nomogram based on ultrasound has been approved as a promising indicator with high clinical utility. It is the first application of ultrasound-based radiomics nomogram to distinguish drug-sensitive breast cancers.
引用
- Zhang, Du, Zha, et al. Construction and validation of a personalized nomogram of ultrasound for pretreatment prediction of breast cancer patients sensitive to neoadjuvant chemotherapy. Br J Radiol. 2022. PMID: 36378247. doi:10.1259/bjr.20220626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。